Biotech Distilled
Substack ↗ Subscribe
Subscribe Substack ↗ About

Home › Modalities › Protein

Protein (97 companies)

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ABSI Absci DermatologyGI/Hepatology+1 6 Phase 1 $1.75B 6
ACIU AC Immune Neurology Rare 5 Phase 3 $222M 11
ACRS Aclaris Therapeutics DermatologyGI/Hepatology+1 Rare 4 Phase 2 $619M 8
ABOS Acumen Pharmaceuticals Neurology 4 Phase 2 $16.2M 4
ADAG Adagene Oncology 10 Phase 2 $134M 10
ADCT ADC Therapeutics Oncology 5 Approved $202M 5
ADMA Adma Biologics ImmunologyInfectious Disease Rare 4 Approved $2.82B 4
AGMB Agomab Therapeutics ImmunologyRespiratory Rare 2 Phase 2 $376M 4
AKBA Akebia Therapeutics HematologyOphthalmology+2 Rare 3 Approved $111M 10
ANAB AnaptysBio DermatologyGI/Hepatology+2 Rare 9 Approved $1.39B 9
ANIX Anixa Biosciences Oncology 2 Phase 1 $111M 3
ANNX Annexon HematologyNeurology+2 Rare 5 Phase 3 $796M 6
APGE Apogee Therapeutics DermatologyGI/Hepatology+1 Rare 9 Phase 2 — 9
APVO Aptevo Therapeutics Oncology 8 Phase 1 $2.2M 8
RCUS Arcus Biosciences DermatologyImmunology+1 3 Phase 3 $2.63B 8
BEAM Beam Therapeutics HematologyMetabolic+1 Rare 1 Phase 2 $2.73B 6
BCAX Bicara Therapeutics Oncology 4 Phase 2 $572M 4
BCRX Biocryst Pharmaceuticals DermatologyImmunology+1 Rare 2 Approved $1.98B 4
BCTX BriaCell Therapeutics Oncology 1 Phase 3 $34.5M 8
CAPR Capricor Therapeutics Infectious DiseaseNeurology Rare 1 NDA Submitted $523M 2
CLDX Celldex Therapeutics DermatologyImmunology+1 9 Phase 3 $2.35B 9
CMMB Chemomab Therapeutics GI/HepatologyImmunology+1 Rare 4 Phase 2 $10.6M 4
CLYM Climb Bio HematologyImmunology+1 Rare 7 Phase 2 $604M 8
CHRS Coherus Oncology Oncology 4 Approved $119M 4
CMPX Compass Therapeutics Oncology 15 Phase 2 $137M 15
CGEN Compugen Oncology 7 Phase 3 $186M 7
CNTB Connect Biopharma Respiratory 4 Phase 2 $45.9M 4
CRVS Corvus Pharmaceuticals DermatologyOncology+1 Rare 1 Phase 3 $889M 7
COYA Coya Therapeutics Neurology Rare 4 Phase 2 $70.1M 6
CBIO Crescent Biopharma Oncology 10 Phase 2 $503M 10
CUE Cue Biopharma ImmunologyOncology 6 Phase 2 $136M 6
CGEM Cullinan Therapeutics HematologyImmunology+2 Rare 9 NDA Submitted $728M 10
CYDY CytoDyn NeurologyOncology 3 Phase 2 $338M 3
CTMX CytomX Therapeutics Oncology 7 Phase 1 $477M 7
DBVT DBV Technologies Immunology 2 NDA Submitted $3.29B 2
IRON Disc Medicine GI/HepatologyHematology+2 Rare 6 Phase 3 $3.59B 9
DYN Dyne Therapeutics MetabolicNeurology Rare 1 NDA Submitted $3.39B 10
ELDN Eledon Pharmaceuticals ImmunologyMetabolic+1 Rare 3 Phase 2 $212M 3
ERAS Erasca Oncology 1 Phase 1 $5.04B 5
ETON Eton Pharmaceuticals GI/HepatologyInfectious Disease+3 Rare 2 Approved $1.63B 17
EVMN Evommune DermatologyImmunology+1 3 Phase 2 $241M 6
EXEL Exelixis CardiovascularOncology 6 Approved $17.0B 23
FBRX Forte Biosciences DermatologyGI/Hepatology 3 Phase 2 — 3
FBIO Fortress Biotech DermatologyHematology+3 Rare 3 Approved $61.7M 12
HROW Harrow Ophthalmology Rare 2 Approved $1.01B 15
IDYA IDEAYA Biosciences Oncology 3 NDA Submitted $3.02B 14
IMTX Immatics Oncology 6 Phase 3 $968M 8
IBRX ImmunityBio Infectious DiseaseOncology 6 Approved $9.15B 16
IMCR Immunocore DermatologyInfectious Disease+2 15 Approved $1.60B 15
IMNM Immunome Oncology Rare 7 NDA Submitted $2.13B 9
IMVT Immunovant ImmunologyNeurology Rare 5 Phase 3 $6.31B 5
INAB IN8bio ImmunologyOncology 1 Phase 1 $10.0M 4
INBX Inhibrx Biosciences Oncology 6 NDA Submitted $1.24B 6
INSM Insmed CardiovascularImmunology+3 Rare 3 Approved $25.1B 15
IVVD Invivyd Infectious Disease 5 Approved $166M 5
JBIO Jade Biosciences ImmunologyRenal Rare 4 Phase 2 $958M 4
JANX Janux Therapeutics Oncology 4 Phase 1 $1.08B 4
KAPA Kairos Pharma Oncology 4 Phase 2 — 13
KROS Keros Therapeutics NeurologyOncology Rare 4 Phase 3 $184M 5
KOD Kodiak Sciences Ophthalmology 8 Phase 3 $6.24B 8
LRMR Larimar Therapeutics Neurology Rare 1 NDA Submitted $248M 1
LXEO Lexeo Therapeutics CardiovascularNeurology Rare 1 Phase 2 $237M 12
MDNAF Medicenna Therapeutics Oncology 10 Phase 2 $29.5M 10
MLTX MoonLake Immunotherapeutics DermatologyImmunology Rare 4 NDA Submitted $981M 4
NKTR Nektar Therapeutics DermatologyImmunology+2 11 Phase 3 $1.27B 11
NBP NovaBridge Biosciences OncologyOphthalmology 7 Phase 2 $106M 7
OCGN Ocugen Infectious DiseaseOphthalmology Rare 3 Phase 3 $314M 12
OCS Oculis Holding NeurologyOphthalmology Rare 1 Phase 3 $417M 5
OMER Omeros HematologyNeurology+2 Rare 4 Approved $1.22B 6
ORKA Oruka Therapeutics DermatologyImmunology Rare 6 Phase 2 $6.81B 7
OTLK Outlook Therapeutics Ophthalmology 3 Approved $106M 3
PMN ProMIS Neurosciences Neurology Rare 6 Phase 1 $37.3M 6
QTTB Q32 Bio Dermatology 3 Phase 2 $277M 3
SABS SAB Biotherapeutics Metabolic 1 Phase 2 $273M 1
SPRB Spruce Biosciences Metabolic Rare 2 Preclinical $134M 2
SYRE Spyre Therapeutics DermatologyImmunology Rare 10 Phase 2 $9.86B 10
SMMT Summit Therapeutics Oncology 6 NDA Submitted $13.1B 6
STRO Sutro Biopharma Oncology 4 Phase 1 $160M 4
SNDX Syndax Pharmaceuticals ImmunologyOncology Rare 1 Approved $852M 7
TECX Tectonic Therapeutic Cardiovascular Rare 4 Phase 2 $412M 4
TLX Telix Pharmaceuticals Oncology 11 Approved $3.27B 25
TGTX Tg Therapeutics Neurology Rare 5 Approved $9.16B 6
TLSA Tiziana Life Sciences ImmunologyNeurology Rare 5 Phase 2 $87.8M 5
TVTX Travere Therapeutics MetabolicRenal Rare 1 Approved $4.76B 7
HURA TuHURA Biosciences Oncology 1 Phase 3 $104M 4
RARE Ultragenyx Pharmaceutical CardiovascularMetabolic+1 Rare 5 Approved $1.57B 10
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $231M 27
PCVX Vaxcyte Infectious Disease 7 Phase 3 $10.1B 7
VERA Vera Therapeutics Infectious DiseaseRenal Rare 6 Approved $2.15B 6
VIR Vir Biotechnology Infectious DiseaseOncology Rare 12 Phase 3 $2.09B 12
VRDN Viridian Therapeutics ImmunologyOphthalmology 7 Approved $3.24B 7
VOR Vor Biopharma ImmunologyNeurology Rare 2 Phase 3 $1.22B 2
VYGR Voyager Therapeutics MetabolicNeurology Rare 1 Phase 1 $116M 9
XNCR Xencor ImmunologyNeurology+1 Rare 28 Approved $2.68B 28
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 7 NDA Submitted $1.92B 11
ZURA Zura Bio DermatologyImmunology Rare 5 Phase 2 $394M 5
ZYME Zymeworks OncologyRespiratory 11 Approved $2.10B 11